Last reviewed · How we verify
Leukaemomycin D (daunorubicinol)
Leukaemomycin D (generic name: daunorubicinol) is a daunorubicinol drug. It is currently FDA-approved.
At a glance
| Generic name | daunorubicinol |
|---|---|
| Drug class | daunorubicinol |
| Target | Multidrug resistance-associated protein 6, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Multicenter, Phase 1, Open-Label Study of the FGFR Inhibitor Pemigatinib (INCB054828) Administered After Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With Adverse or Intermediate Ris (Phase 1)
- A Randomized Phase 2 Trial to Evaluate the Efficacy of BCL-2 Inhibitor Therapy With Chemotherapy Compared to Chemotherapy Alone in Adult Patients With Newly Diagnosed T-Cell ALL and T-Cell Lymphoblast (Phase 2)
- A Phase II Randomized Clinical Trial of Venetoclax Combined With FLAG IDA Induction and Consolidation Compared to Standard of Care for Newly Diagnosed Patients With Acute Myeloid Leukemia (Phase 2)
- Clinical Evaluation of ASTX727 in Combination With Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients With ELN High- Risk A (Phase 1)
- A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) (Phase 3)
- A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearra (Phase 1)
- A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy (Phase 2)
- A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leukaemomycin D CI brief — competitive landscape report
- Leukaemomycin D updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Leukaemomycin D
What is Leukaemomycin D?
Leukaemomycin D (daunorubicinol) is a daunorubicinol drug.
What is the generic name of Leukaemomycin D?
daunorubicinol is the generic (nonproprietary) name of Leukaemomycin D.
What drug class is Leukaemomycin D in?
Leukaemomycin D belongs to the daunorubicinol class. See all daunorubicinol drugs at /class/daunorubicinol.
What development phase is Leukaemomycin D in?
Leukaemomycin D is FDA-approved (marketed).
What does Leukaemomycin D target?
Leukaemomycin D targets Multidrug resistance-associated protein 6, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1 and is a daunorubicinol.
Related
- Drug class: All daunorubicinol drugs
- Target: All drugs targeting Multidrug resistance-associated protein 6, ATP-binding cassette sub-family G member 2, Multidrug resistance protein 1
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing